US FDA imposes partial clinical hold on Biohaven epilepsy trials
Biohaven said the U.S. FDA imposed a partial clinical hold, pausing new patient enrollment in its experimental epilepsy drug trials after rodent findings. The company’s shares fell more than 13% in premarket trading.